Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MICROSOFT CORPORATION

(MSFT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Microsoft : Novartis empowers scientists with AI to speed the discovery and development of breakthrough medicines

11/18/2021 | 09:13am EST

"Normally, they do this manually, reading through all of these documents to find out what is relevant to the question they have in mind," Finelli says.

"Here, AI can actually help to do this in a few clicks and bring the relevant information back to the user for further use, informing them how to design future experiments to find new ways to create a formulation for a new drug," Finelli adds.

Novartis researchers also are leveraging Microsoft Azure in their work.

Eventually, scientists at Novartis aim to use computer models to help predict promising molecular structures or to reveal which experiments might be most useful in testing, maintaining quality while shortcutting a testing process that now can take years.

"Now you can do 10,000 experiments simultaneously, get the results, then use those to design the next 10,000 experiments," Bishop says.

"So the revolution is beginning to unfold. Deep learning is completely changing the way we think about simulating physical systems - it might be (simulating) two galaxies colliding or weather systems or the climate. And it might be small molecules binding with proteins - in other words, the whole process of how drugs work," Bishop adds.

To conduct its molecular simulations, Novartis relies on expertise provided by the Microsoft Research Lab in Cambridge and, in smaller ways, by ongoing work occurring at Microsoft Research Labs in Amsterdam, Beijing and Redmond, Washington, Bishop says.

But at the center of all that discovery, humans continue to be the most vital engine.

As part of its strategic partnership with Microsoft, Novartis is bringing AI to the desktop of every company associate. At Novartis, they call this "the enablement of citizen data scientists."

"Business is becoming increasingly data driven. The way I see it, one needs to embed AI-based tools - small engines of AI - into every aspect of an organization's operation, so a person who is not necessarily a data scientist can have higher-quality, faster decision making," Ebadollahi says.

This rising concept, also known as the democratization of AI, gives people the ability to use AI to tap into the wealth of data available and derive novel insights and discover breakthrough treatments that improve and extend peoples' lives.

"That is why we are even doing this work, that is the higher purpose," Ebadollahi says. "At Novartis, we are impacting human lives through the medicines that we develop. You can't be a data scientist or a machine learning expert and not have that in the back of your mind every day."

For Ebadollahi, who spends much of his time focusing on the deep intricacies of datasets and machine learning, there's always mental space for loved ones, family members and friends who are dealing with health problems.

Those are the human touchpoints, he says, that help to energize his mission, that clarify what every workday should really be about. It is their faces that sometimes enter his thoughts alongside the latest tech responsibilities on his plate.

"At a medicines company, you hear about the ailments, the diseases for which these fantastic scientists, biologists and chemists are in search of the drug," Ebadollahi says. "It's very, very present in the atmosphere.

"In the thick of the work, in the day-to-day of business, you might get lost in the noise a little bit, but it's good to step back and look at why you are doing what you're doing. And when I do, those are the pictures I see - the faces of loved ones come to my mind."

Top photo: A Novartis scientist reaches for a vial inside a lab hood. (All photos courtesy of Novartis)

Disclaimer

Microsoft Corporation published this content on 18 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2021 14:12:09 UTC.


ę Publicnow 2021
All news about MICROSOFT CORPORATION
01/20Analysis-Microsoft faces challenge cleaning up Activision Blizzard's culture
RE
01/20SOCIAL BUZZ : Wallstreetbets Stocks Mostly Rally; Peloton Slumps 25%
MT
01/20Vuzix's Smart Glasses Now Compatible With Microsoft Endpoint Manager
MT
01/20Bargain-hunting buoys Wall Street after Nasdaq correction
RE
01/20MICROSOFT : Building a stronger cybersecurity team through diversity and training
PU
01/20SEE WHAT'S NEXT IN EDUCATION : Join us at upcoming FETC and TCEA events
PU
01/20Microsoft Likely to Post Strong Fiscal Q2 Results as Azure, Office365, Windows Drive Ga..
MT
01/20TENCENT VS SONY VS MICROSOFT : Fight!
01/20MICROSOFT : adds to its commitment to affordable housing in Puget Sound region
PU
01/20Wall Street rallies as bond sell-off pauses, oil gains
RE
More news
Analyst Recommendations on MICROSOFT CORPORATION
More recommendations
Financials (USD)
Sales 2022 197 B - -
Net income 2022 71 463 M - -
Net cash 2022 89 063 M - -
P/E ratio 2022 31,7x
Yield 2022 0,78%
Capitalization 2 264 B 2 264 B -
EV / Sales 2022 11,1x
EV / Sales 2023 9,59x
Nbr of Employees 181 000
Free-Float 99,9%
Chart MICROSOFT CORPORATION
Duration : Period :
Microsoft Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MICROSOFT CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 45
Last Close Price 301,60 $
Average target price 373,06 $
Spread / Average Target 23,7%
EPS Revisions
Managers and Directors
Satya Nadella Chairman & Chief Executive Officer
Bradford L. Smith President & Chief Legal Officer
Amy E. Hood Chief Financial Officer & Executive Vice President
James Kevin Scott Chief Technology Officer & Executive VP
Matthias Troyer Partner Research Manager
Sector and Competitors
1st jan.Capi. (M$)
MICROSOFT CORPORATION-10.32%2 264 407
SEA LIMITED-23.98%95 563
ATLASSIAN CORPORATION PLC-23.60%73 632
DASSAULT SYSTÈMES SE-11.66%68 940
SYNOPSYS INC.-15.89%47 560
ZOOM VIDEO COMMUNICATIONS, INC.-15.28%46 431